Seres Therapeutics begins phase 1b trial of SER-301 in ulcerative colitis
Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). According to the US-based biotech company, SER-301 is an oral fermented microbiome therapeutic designed for dampening the unusual gastrointestinal inflammation central to ulcerative colitis and promote clinical remission in […]
Bristol Myers Squibb (BMS) said that the phase 3 True North clinical trial evaluating Zeposia (ozanimod) in adult patients with moderate to severe ulcerative colitis (UC) met both primary endpoints. The placebo-controlled late stage trial featuring 645 patients assessed oral Zeposia as an induction and maintenance therapy for the chronic inflammatory bowel disease (IBD). ZEPOSIA […]
Continue reading …
Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates for the treatment of inflammatory bowel disease (IBD). The companies will also collaborate on detecting biomarkers related to clinical response for a maximum of five pipeline compounds of Gilead Sciences, […]
Continue reading …
Business News Today
- Dam Nai wind farm Vietnam to be acquired by SN Power
- TRATON to take full ownership of US truck manufacturer Navistar for $3.7bn
- Elizabeth River Tunnels Project : Skanska to sell 50% stake for $625m
- Spanish proptech company Clikalia secures investment from Mouro Capital
- Orange Romania to acquire 54% stake in Telekom Romania Communications
- Carlyle Group invests $250m in US e-commerce company Pharmapacks
- Cano Health to merge with blank check company Jaws Acquisition in $4.4bn deal
- Naturgy to sell stake in Chilean utility CGE to China’s SGI for €2.5bn
- Arthur J. Gallagher acquires wholesale insurance broker AWIS Group
- Hub acquires insurance brokerage assets of Larry Dean Massey, Jr.
